Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 5/20 | 0.51 |
| ▸ | F2 | P00734 | 7/20 | 0.50 |
| ▸ | PRCP | P42785 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | XIAP | P98170 | 1/20 | 0.44 |
| ▸ | MLX | Q9UH92 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24648734 | 0.81 | DPP4 (0.50) | F2XIAP | |
| SCHEMBL8536863 | 0.80 | DPP4 (0.49) | F2OPRD1 | |
| SCHEMBL13010415 | 0.78 | F2 (0.69) | F2 | |
| SCHEMBL6245876 | 0.78 | DPP4 (0.53) | FKBP1AF2XIAPCYP3A4 | |
| SCHEMBL6243789 | 0.78 | DPP4 (0.53) | FKBP1AF2XIAPCYP3A4 | |
| SCHEMBL29615666 | 0.76 | DPP8 (0.52) | F2OPRD1XIAPCYP3A4CYP2C9 | |
| SCHEMBL6243681 | 0.75 | NPSR1 (0.58) | FKBP1AF2PRCPXIAP | |
| SCHEMBL10956267 | 0.74 | PREP (0.64) | PRCPCYP3A4CYP2C9 | |
| SCHEMBL10954962 | 0.73 | PRCP (0.75) | PRCPCYP3A4CYP2C9 | |
| SCHEMBL8072499 | 0.73 | DPP4 (0.60) | F2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |